Metvix (Methyl Aminolevulinate)

Methyl aminolevulinate penetrates skin cells and is converted into protoporphyrin IX, a photosensitizer. When the area is illuminated with a specific wavelength of visible light, protoporphyrin IX generates reactive oxygen species that selectively destroy dysplastic cells while sparing normal tissue, leading to lesion clearance.

The prescribed amount of Metvix is determined by the treating physician based on the size of the treatment field, lesion severity, and patient characteristics. The clinician decides the exact quantity to apply and the illumination protocol, ensuring safe and effective therapy.

The safety of Metvix in pregnancy and lactation has not been established. It is classified as having an unknown pregnancy category, so it should be avoided unless the potential therapeutic benefit justifies the potential risk to the fetus or infant.

To request Metvix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metvix offers a field‑directed photodynamic approach that can treat multiple lesions simultaneously, unlike lesion‑focused procedures such as cryotherapy or topical 5‑fluorouracil, which target individual spots. Photodynamic therapy may provide better cosmetic outcomes and lower recurrence rates for extensive sun‑damaged areas.

Metvix should be stored at temperatures below 25 °C in its original packaging. Keep the cream away from moisture, direct sunlight and excessive heat. Ensure the container is tightly closed to maintain product stability.

Metvix is applied topically to the affected skin area by a healthcare professional. After a specified incubation period, the treated skin is illuminated with a calibrated visible‑light source. The entire procedure is performed under controlled clinical conditions.

Serious risks include severe photosensitivity reactions that may extend beyond the treated field, secondary skin infections, allergic contact dermatitis, and persistent hyper‑ or hypopigmentation. Patients should be monitored closely for any signs of these complications.

Metvix should not be used on patients with known hypersensitivity to methyl aminolevulinate or any cream excipients, on broken or infected skin, and in individuals where the safety during pregnancy or lactation cannot be assured. It is also contraindicated in patients taking systemic photosensitizing agents.